PDCD1 and hepatocellular carcinoma: To date, the approved ICIs in the treatment of HCC included the anti-PD1 inhibitors nivolumab and pembrolizumab, the anti-PDL1 inhibitor atezolizumab, and the anti-CTLA-4 ipilimumab (Figure 2).